Lynch syndrome (LS) is an autosomal dominant condition characterized by an increased risk of hereditary colorectal, endometrial, ovarian, pancreatic, urinary tract, and gastric cancer.
It is estimated that around 5% of all endometrial cancer (EC) cases are due to an inherited predisposition, of which LS might be the most frequent. The lifetime risk of developing EC in women with LS ranges between 40% and 71% depending on the type of mutation. In many cases, this risk may even exceed their risk of developing colon cancer. Moreover, in 60% of these women, EC will be the first primary malignancy diagnosed and the sentinel diagnosis of the syndrome. Therefore, it is essential to identify which women with EC have LS in order to allow implementation of individualized screening and preventive strategies.
DunlopMG, FarringtonSM, CarothersAD, Cancer risk associated with germline DNA mismatch repair gene mutations.Hum Mol Genet.1997;6(1):105–110.
2.
WatsonP, VasenHFA, MecklinJ-P, The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.Int J Cancer.2008;123(2):444–449.
3.
AarnioM, SankilaR, PukkalaE, Cancer risk in mutation carriers of DNA-mismatch-repair genes.Int J Cancer.1999;81(2):214–218.
4.
VasenHF, StormorkenA, MenkoFH, MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.J Clin Oncol.2001;19(20):4074–4080.
5.
HampelH, StephensJA, PukkalaE, Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.Gastroenterology.2005;129(2):415–421.
6.
BannoK, SusumuN, YanokuraM, Association of HNPCC and endometrial cancers.Int J Clin Oncol.2004;9(4):262–269.
7.
KobayashiK, MatsushimaM, KoiS, Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability.Jpn J Cancer Res.1996;87(2):141–145.
8.
KowalskiLD, MutchDG, HerzogTJ, RaderJS, GoodfellowPJ.Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers.Genes Chromosomes Cancer.1997;18(3):219–227.
9.
LimPC, TesterD, ClibyW, Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability.Clin Cancer Res.1996;2(11):1907–1911.
10.
BerendsMJ, HollemaH, WuY, MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer.Int J Cancer.2001;92(3):398–403.
11.
BerendsMJW, WuY, SijmonsRH, Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.J Clin Oncol.2003;21(23):4364–4370.
12.
CharamesGS, MillarAL, PalT, NarodS, BapatB.Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium?Hum Genet.2000;107(6):623–629.
13.
MillarAL, PalT, MadlenskyL, Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium.Hum Mol Genet.1999;8(5):823–829.
14.
OllikainenM, Abdel-RahmanWM, MoisioA-L, Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?J Clin Oncol.2005;23(21):4609–4616.
15.
ChadwickRB, PyattRE, NiemannTH, Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma.J Med Genet.2001;38(7):461–466.
16.
GoodfellowPJ, ButtinBM, HerzogTJ, Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.Proc Natl Acad Sci USA.2003;100(10):5908–5913.
17.
BonadonaV, BonaïtiB, OIschwangS, ; French Cancer Genetics Network.Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.JAMA.2011;305(22):2304–2310.
18.
ObermairA, YouldenDR, YoungJP, Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.Int J Cancer.2010;127(11):2678–2684.
19.
HendriksYMC, WagnerA, MorreauH, Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.Gastroenterology.2004;127(1):17–25.
20.
WatsonP, VasenHF, MecklinJP, JärvinenH, LynchHT.The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer.Am J Med.1994;96(6):516–520.
21.
LuKH, DinhM, KohlmannW, Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome.Obstet Gynecol.2005;105(3):569–574.
22.
LynchHT, HarrisRE, LynchPM, GuirgisHA, LynchJF, BardawilWA.Role of heredity in multiple primary cancer.Cancer.1977;40(4)(Suppl):1849–1854.
23.
de JongAE, HendriksYMC, KleibeukerJH, Decrease in mortality in Lynch syndrome families because of surveillance.Gastroenterology.2006;130(3):665–671.
24.
JärvinenHJ, AarnioM.Surveillance on mutation carriers of DNA mismatch repair genes.Ann Chir Gynaecol.2000;89(3):207–210.
25.
StupartDA, GoldbergPA, AlgarU, RamesarR.Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation.Colorectal Dis.2009;11(2):126–130.
26.
KwonJS, ScottJL, GilksCB, DanielsMS, SunCC, LuKH.Testing women with endometrial cancer to detect Lynch syndrome.J Clin Oncol.2011;29(16):2247–2252.
27.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives.Genet Med Off J Am Coll Med Genet.2009;11(1):35–41.
28.
HealdB, PlesecT, LiuX, Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center.J Clin Oncol.2013;31(10):1336–1340.
29.
ResnickK, StraughnJMJr, BackesF, HampelH, MatthewsKS, CohnDE.Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients.Obstet Gynecol.2009;114(3):530–536.
30.
VasenHF, WatsonP, MecklinJP, LynchHT.New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.Gastroenterology.1999;116(6):1453–1456.
31.
UmarA, BolandCR, TerdimanJP, Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.J Natl Cancer Inst.2004;96(4):261–268.
32.
HampelH, FrankelWL, MartinE, Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).N Engl J Med.2005;352(18):1851–1860.
33.
HampelH, PanescuJ, LockmanJ, Comment on: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.Cancer Res.2007;67(19):9603.
34.
RyanP, MulliganAM, AronsonM, Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.Cancer.2012;118(3):681–688.
35.
RamsoekhD, WagnerA, van LeerdamME, A high incidence of MSH6 mutations in Amsterdam criteria 11-negative families tested in a diagnostic setting.Gut.2008;57(11):1539–1544.
36.
HampelH, FrankelWL, MartinE, Feasibility of screening for Lynch syndrome among patients with colorectal cancer.J Clin Oncol.2008;26(35):5783–5788.
37.
JulieC, TrésalletC, BrouquetA, Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening.Am J Gastroenterol.2008;103(11):2825–2835, quiz 2836.
38.
van LierMGF, LeenenCHM, WagnerA, ; LIMO Study Group. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.J Pathol.2012;226(5):764–774.
39.
MoreiraL, BalaguerF, LindorN, ; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer.JAMA.2012;308(15):1555–1565.
40.
CanardG, LefevreJH, ColasC, Screening for Lynch syndrome in colorectal cancer: are we doing enough?Ann Surg Oncol.2012;19(3):809–816.
41.
Pérez-CarbonellL, Ruiz-PonteC, GuarinosC, Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.Gut.2012;61(6):865–872.
42.
MvunduraM, GrosseSD, HampelH, PalomakiGE.The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.Genet Med.2010;12(2):93–104.
43.
LadabaumU, WangG, TerdimanJ, Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.Ann Intern Med.2011;155(2):69–79.
44.
HampelH, FrankelW, PanescuJ, Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.Cancer Res.2006;66(15):7810–7817.
45.
LeenenCHM, van LierMGF, van DoomHC, Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤70 years.Gynecol Oncol.2012;125(2):414–420.
46.
FergusonSE, AronsonM, PollettA, Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.Cancer.2014;120(24):3932–3939.
47.
MolineJ, MahdiH, YangB, Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.Gynecol Oncol.2013;130(1):121–126.
48.
EgoavilC, AlendaC, CastillejoA, Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers.PLoS ONE.2013;8(11):e79737.
49.
SanchezJA, VogelJD, KaladyMF, BronnerMP, SkacelM, ChurchJM.Identifying Lynch syndrome: we are all responsible.Dis Colon Rectum.2008;51(12):1750–1756.
50.
BroaddusRR, LynchHT, ChenL-M, Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma.Cancer.2006;106(1):87–94.
51.
PalaciosJ, AlendaC, LujanD.Pathological features of endometrial cancer in patients with Lynch syndrome.Lab Invest.2010;90(suppl 1):258A.
52.
CarcangiuML, RadiceP, CasaliniP, BertarioL, MerolaM, SalaP.Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.Int J Surg Pathol.2010;18(1):21–26.
53.
van den BosM, van den HovenM, JongejanE, More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon.Am J Surg Pathol.2004;28(6):706–711.
54.
de LeeuwWJ, DierssenJ, VasenHF, Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients.J Pathol.2000;192(3):328–335.
55.
WestinSN, LacourRA, UrbauerDL, Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.J Clin Oncol.2008;26(36):5965–5971.
56.
ClarkeBA, CooperK.Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas.Adv Anat Pathol.2012;19(4):231–238.
57.
WalshMD, CummingsMC, BuchananDD, Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.Clin Cancer Res.2008;14(6):1692–1700.
58.
HonoréLH, HansonJ, AndrewSE.Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables.Int J Gynecol Cancer.2006;16(3):1386–1392.
59.
ToledoG, GrowdonW, Dias-SantagataD.Microsatellite instability status and clinicopathologic profile of endometrial cancer (EC) in young women (<50 years).Mod Pathol.2008;21(suppl l): Abstract 1036.
60.
AarnioM, MecklinJP, AaltonenLA, Nyström-LahtiM, JärvinenHJ.Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.Int J Cancer.1995; 64(6):430–433.
61.
VasenHF, WatsonP, MecklinJP, The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer.Anticancer Res.1994;14(4B):1675–1678.
62.
MatthewsKS, EstesJM, ConnerMG, Lynch syndrome in women less than 50 years of age with endometrial cancer.Obstet Gynecol.2008;111(5):1161–1166.
63.
WalshCS, BlumA, WaltsA, Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.Gynecol Oncol.2010;116(3):516–521.
64.
LuKH, SchorgeJO, RodabaughKJ, Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.J Clin Oncol.2007;25(33):5158–5164.
65.
DjordjevicB, BroaddusR.Conventional screening criteria may miss a high proportion of Lynch syndrome patients with endometrial carcinoma due to PMS2 loss.Mod Pathol.2012;25 (suppl 2): Abstract 1118.
66.
BackesFJ, LeonME, IvanovI, Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.Gynecol Oncol.2009;114(3):486–490.
67.
LoukolaA, EklinK, LaihoP, Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC).Cancer Res.2001;61(11):4545–4549.
68.
EstellerM, LevineR, BaylinSB, EllensonLH, HermanJG.MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas.Oncogene.1998;17(18):2413–2417.
69.
PeltomäkiP.Role of DNA mismatch repair defects in the pathogenesis of human cancer.J Clin Oncol.2003;21(6):1174–1179.
70.
SimpkinsSB, BockerT, SwisherEM, MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers.Hum Mol Genet.1999;8(4):661–666.
71.
BolandCR, ShikeM.Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer.Gastroenterology.2010;138(7):2197.
72.
ModicaI, SoslowRA, BlackD, TornosC, KauffN, ShiaJ.Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.Am J Surg Pathol.2007;31(5):744–751.
73.
BuchananDD, TanYY, WalshMD, Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.J Clin Oncol.2014;32(2):90–100.
74.
SolimanPT, BroaddusRR, SchmelerKM, Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?J Clin Oncol.2005;23(36):9344–9350.
75.
LancasterJM, PowellCB, KauffND, ; Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.Gynecol Oncol.2007;107(2):159–162.
76.
TanYY, McGaughranJ, FergusonK, ; ANECS Group. Improving identification of lynch syndrome patients: a comparison of research data with clinical records.Int J Cancer.2013;132(12):2876–2883.
